| Title | AMT: preclinical pharmacology studies. | | Author(s) | Niazi F, Drevs J, Diergarten K, Dorn A, Maier A, Fiebig HH, Bruyns E, Scheele J | | Institution | Auron Healthcare GmbH, 79100 Freiburg, Germany. | | Source | Int J Oncol 2009 May; 34(5):1341-52. | | MeSH | Animals
Antineoplastic Combined Chemotherapy Protocols
Calcium
Cells, Cultured
Chamomile
Chlorpheniramine
Drug Evaluation, Preclinical
Humans
Insulin
Mice
Neoplasms
Organ Specificity
Phytotherapy
Plant Extracts
Treatment Outcome
| | Abstract | Auron-Misheil-Therapy (AMT) consisting of aqueous camomile extract supplemented with calcium, vitamins, the antihistamine chlorpheniramine and human insulin is under development as anti-cancer treatment. AMT was preclinically investigated in tumour cell lines and tumour xenografts to guide clinical phase I/II studies. AMT was tested against 56 human tumour cell lines, in a clonogenic assay in 98 patient-derived xenografts and in in vivo studies. AMT showed in vitro cytotoxic activity with highest susceptibility in cervical cancer, glioblastoma and colon cancers. In the clonogenic assay, anti- cancer activity of AMT was most active in cervical and uterine tumours, in colon cancer, glioblastoma, leukaemia, melanoma and pancreatic cancer. In vivo, AMT showed slight activity in tumour xenograft models of colon and mammary cancer. It also showed immune stimulatory effects by induction of IL-6- and TNF-alpha secretion in human PBMCs. The immune stimulatory potential of AMT, together with slight anti-tumour efficacy observed in the present study, indicates a role of AMT in tumour therapy. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19360346 |
|
